本季度信息
截至2025年12月31日止六个月，国药科技股份有限公司实现营收约26,800,000港元，同比上升42%。经调整净亏损约3,800,000港元，相较上一年同期的亏损幅度有所收窄。毛利率约为19.9%，上一年同期约为34.4%。经营利润率为-5.7%（经营亏损1,539,000港元占收入比），而上年同期经营亏损1,075,000港元。期内经营现金流净流出781,000港元，而上一年同期则为流入1,988,000港元。
从费用结构看，销售及分销开支比上一年度有所下降，管理及经营开支略有上升。销售及分销开支为1,072,000港元，较上一年度的3,029,000港元下降幅度明显。管理及经营开支为5,794,000港元，较上一年同期的5,451,000港元小幅上升。
业务分项
公司主要通过供应链服务业务取得收入。报告期内，该业务营收约26,800,000港元，同比增长42%。公司在此期间继续聚焦大健康产业相关供应链的分销网络与数智化升级，利用数据分析与整合能力加快产品配送与市场覆盖，带动收入增长。解決方案服务本期未披露具体收入。
高管解读
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.